H Doi1,2, K Tamari3,4, N Masai3, Y Akino3,4, D Tatsumi3, H Shiomi3,4, R-J Oh3. 1. Miyakojima IGRT Clinic, 1-16-22 Miyakojimahondori, Miyakojima-ku, Osaka, 534-0021, Japan. h-doi@med.kindai.ac.jp. 2. Department of Radiation Oncology, Faculty of Medicine, Kindai University, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka, 589-8511, Japan. h-doi@med.kindai.ac.jp. 3. Miyakojima IGRT Clinic, 1-16-22 Miyakojimahondori, Miyakojima-ku, Osaka, 534-0021, Japan. 4. Department of Radiation Oncology, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Abstract
PURPOSE: This study sought to discern the clinical outcomes of intensity-modulated radiation therapy (IMRT) administered to the spine in patients who had undergone previous radiotherapy. METHODS: A total of 81 sites of 74 patients who underwent previous radiotherapy administered to the spine or peri-spine and subsequently received IMRT for the spine were analyzed in this study. The prescribed dose of 80 Gy in a biologically effective dose (BED) of α/β = 10 (BED10) was set as the planning target volume. The constraint for the spinal cord and cauda equine was D0.1 cc ≤ 100 Gy and ≤ 150 Gy of BED for re-irradiation alone and the total irradiation dose, respectively. RESULTS: The median follow-up period was 10.1 (0.9-92.1) months after re-irradiation, while the median interval from the last day of the previous radiotherapy to the time of re-irradiation was 15.6 (0.4-210.1) months. Separately, the median prescript dose of re-irradiation was 78.0 (28.0-104.9) of BED10. The median survival time in this study was 13.9 months, with 1-, 3-, and 5-year overall survival rates of 53.7%, 29.3%, and 26.6%, respectively. The 1-, 3-, and 5-year local control rates were 90.8%, 84.0%, and 84.0%, respectively. Neurotoxicity was observed in two of 72 treatments (2.8%) assessed after re-irradiation. CONCLUSION: Re-irradiation for the spine using IMRT seems well-tolerated. Definitive re-irradiation can be a feasible treatment option in patients with the potential for a good prognosis.
PURPOSE: This study sought to discern the clinical outcomes of intensity-modulated radiation therapy (IMRT) administered to the spine in patients who had undergone previous radiotherapy. METHODS: A total of 81 sites of 74 patients who underwent previous radiotherapy administered to the spine or peri-spine and subsequently received IMRT for the spine were analyzed in this study. The prescribed dose of 80 Gy in a biologically effective dose (BED) of α/β = 10 (BED10) was set as the planning target volume. The constraint for the spinal cord and cauda equine was D0.1 cc ≤ 100 Gy and ≤ 150 Gy of BED for re-irradiation alone and the total irradiation dose, respectively. RESULTS: The median follow-up period was 10.1 (0.9-92.1) months after re-irradiation, while the median interval from the last day of the previous radiotherapy to the time of re-irradiation was 15.6 (0.4-210.1) months. Separately, the median prescript dose of re-irradiation was 78.0 (28.0-104.9) of BED10. The median survival time in this study was 13.9 months, with 1-, 3-, and 5-year overall survival rates of 53.7%, 29.3%, and 26.6%, respectively. The 1-, 3-, and 5-year local control rates were 90.8%, 84.0%, and 84.0%, respectively. Neurotoxicity was observed in two of 72 treatments (2.8%) assessed after re-irradiation. CONCLUSION: Re-irradiation for the spine using IMRT seems well-tolerated. Definitive re-irradiation can be a feasible treatment option in patients with the potential for a good prognosis.
Authors: Yvette M van der Linden; Judith J Lok; Elsbeth Steenland; Hendrik Martijn; Hans van Houwelingen; Corrie A M Marijnen; Jan Willem H Leer Journal: Int J Radiat Oncol Biol Phys Date: 2004-06-01 Impact factor: 7.038
Authors: A Sahgal; D Roberge; D Schellenberg; T G Purdie; A Swaminath; J Pantarotto; E Filion; Z Gabos; J Butler; D Letourneau; G L Masucci; L Mulroy; A Bezjak; L A Dawson; M Parliament Journal: Clin Oncol (R Coll Radiol) Date: 2012-05-24 Impact factor: 4.126
Authors: Arjun Sahgal; Mark Bilsky; Eric L Chang; Lijun Ma; Yoshiya Yamada; Laurence D Rhines; Daniel Létourneau; Matthew Foote; Eugene Yu; David A Larson; Michael G Fehlings Journal: J Neurosurg Spine Date: 2010-12-24
Authors: Carsten Nieder; Anca L Grosu; Nicolaus H Andratschke; Michael Molls Journal: Int J Radiat Oncol Biol Phys Date: 2005-03-01 Impact factor: 7.038
Authors: Carsten Nieder; Anca L Grosu; Nicolaus H Andratschke; Michael Molls Journal: Int J Radiat Oncol Biol Phys Date: 2006-11-02 Impact factor: 7.038
Authors: Shayna E Rich; Ronald Chow; Srinivas Raman; K Liang Zeng; Stephen Lutz; Henry Lam; Maurício F Silva; Edward Chow Journal: Radiother Oncol Date: 2018-02-01 Impact factor: 6.280
Authors: Isabelle Thibault; Ameen Al-Omair; Giuseppina Laura Masucci; Laurence Masson-Côté; Fiona Lochray; Renée Korol; Lu Cheng; Wei Xu; Albert Yee; Michael G Fehlings; Georg A Bjarnason; Arjun Sahgal Journal: J Neurosurg Spine Date: 2014-08-29